awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q41530191-FA97E710-968F-4CEA-8677-483D6B912995
Q41530191-FA97E710-968F-4CEA-8677-483D6B912995
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41530191-FA97E710-968F-4CEA-8677-483D6B912995
Are nilotinib-associated vascular adverse events an under-estimated problem?
P2860
Q41530191-FA97E710-968F-4CEA-8677-483D6B912995
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41530191-FA97E710-968F-4CEA-8677-483D6B912995
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
55f3de4ac5823f5e5cd19d9df2743c42ec237e61
P2860
Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study.